Key Points
- Financial Lp Hrt sold 94,462 shares of Onconetix (NASDAQ:ONCO) on April 20 at an average of $0.75 per share for $70,846.50, leaving it with 83,359 shares and representing a 53.12% decrease in its reported ownership.
- Onconetix stock opened at $0.68 (down 7.5%), with a tiny market cap of roughly $446,688 and wide price swings (12‑month high $74.29, low $0.66), underscoring its microcap volatility and risk.
- The same major shareholder conducted multiple buys and sells the prior week (April 14–17), indicating active trading rather than a single one‑off transaction.
Onconetix, Inc. (NASDAQ:ONCO - Get Free Report) major shareholder Financial Lp Hrt bought 34,636 shares of the firm's stock in a transaction that occurred on Friday, April 17th. The stock was bought at an average cost of $0.73 per share, for a total transaction of $25,284.28. Following the completion of the acquisition, the insider owned 177,821 shares in the company, valued at $129,809.33. This trade represents a 24.19% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Major shareholders that own more than 10% of a company's stock are required to disclose their transactions with the SEC.
Financial Lp Hrt also recently made the following trade(s):
- On Thursday, April 16th, Financial Lp Hrt sold 53,867 shares of Onconetix stock. The stock was sold at an average price of $0.73, for a total value of $39,322.91.
- On Monday, April 20th, Financial Lp Hrt sold 94,462 shares of Onconetix stock. The stock was sold at an average price of $0.75, for a total value of $70,846.50.
- On Wednesday, April 15th, Financial Lp Hrt bought 92,554 shares of Onconetix stock. The stock was bought at an average cost of $0.76 per share, for a total transaction of $70,341.04.
- On Tuesday, April 14th, Financial Lp Hrt bought 74,350 shares of Onconetix stock. The stock was bought at an average cost of $0.77 per share, for a total transaction of $57,249.50.
Onconetix Stock Performance
Shares of Onconetix stock opened at $0.68 on Wednesday. Onconetix, Inc. has a one year low of $0.66 and a one year high of $74.29. The stock's fifty day moving average is $2.62 and its 200 day moving average is $8.51. The stock has a market cap of $446,688.00, a P/E ratio of 0.00 and a beta of 3.63.
Institutional Investors Weigh In On Onconetix
An institutional investor recently bought a new position in Onconetix stock. Citadel Advisors LLC purchased a new stake in shares of Onconetix, Inc. (NASDAQ:ONCO - Free Report) during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 15,633 shares of the company's stock, valued at approximately $49,000. Citadel Advisors LLC owned 1.00% of Onconetix as of its most recent SEC filing. 23.89% of the stock is owned by institutional investors and hedge funds.
Onconetix Company Profile
(
Get Free Report)
Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
